Lymphocyte profile in patients with Grave’s disease depending on the degree of its compensation
Journal Title: Міжнародний ендокринологічний журнал - Year 2018, Vol 14, Issue 3
Abstract
Background. In Ukraine today, the main method for the treatment of Grave’s disease (GD) is the administration of antithyroid drugs in order to achieve euthyroidism. At the same time, the leading role in the onset of GD and its relapses belongs to the violation of various links of the immune system, so specification of such disorders remains an urgent task in the development of a system for the prevention of GD relapses. The purpose of this work is to establish the influence of antithyroid drugs on the lymphocyte profile of peripheral blood in patients with GD in order to prescribe adequate immunotropic therapy. Materials and methods. A comparative analysis of peripheral blood lymphocytes was carried out in women with GD on the background of hyperthyroidism and drug compensation. Deviations of individual indicators were established, which could become triggers for disease recurrence. Results. In the group of women with GD during remission after therapy with thyrostatic agents, the normalization of thyroid homeostasis occurred. This was accompanied by a positive dynamics (decrease) in the activity of T-helpers and B-lymphocytes that is necessary to reduce the formation of antibodies. At the same time, there was a decrease in suppressor activity with an increase in the immunoregulatory T-suppression index, as well as the formation of a natural killer deficiency. There was an increase in the CD4/CD16 and CD8/CD16 indices, which indicates the predominance of the antibody-dependent immune process over nonspecific cellular cytotoxicity. Conclusions. GD therapy with thyrostatic drugs not only contributes to medical compensation, but also has an immunomodulatory effect. Lymphogram of peripheral blood in treated patients with GD is characterized by a decrease in T-helper activity and B-lymphocyte level (p < 0.05) that reduces antibody formation, by a decrease in T-suppressors and natural killers (p < 0.001) leading to the disease recurrence. Patients with GD receiving thyrostatic agents require additional administration of immunomodulators (including selenium-containing ones), which can increase suppressor activity.
Authors and Affiliations
O. A. Goncharova
Keywords
Related Articles
- EP ID EP342397
- DOI 10.22141/2224-0721.14.3.2018.136415
- Views 35
- Downloads 0
Incidence of Thyroid Structural Disorders in Patients with Type 2 Diabetes Mellitus
To study the incidence of structural changes of the thyroid gland (TG) in patients with diabetes mellitus (DM) type 2, we have examined 145 patients (75 patients with type 2 DM and obesity, 35 — with DM type 2 without ob...
Adiponectin gene single-nucleotide polymorphisms in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
Background. It is generally believed that environmental and genetic factors interact with the formation of nonalcoholic fatty liver disease (NAFLD) phenotype and determine its progression. Both NAFLD and type 2 diabetes...
Morphological Changes of Pulmonary Bloodstream in Type 2 Diabetic Patients
The pathomorphological investigation of pulmonary vessels found the changes being developed in diabetic microangiopathy in other organs and affecting firstly the morphological structures responsive for respiratory exchan...
Expression of Steroid Hormone Receptors of the Cervix in Cervical Intraepithelial Neoplasia Associated with Human Papillomavirus Infection in Infertile Women
The article presents the results of immunohistochemical study of estrogen and progesterone receptors of the cervix in cervical intraepithelial neoplasia (CIN) associated with human papillomavirus infection (HPI) in 157 w...
The Levels of Apolipoproteins A1 and B in the Blood Serum and Their Ratio in Young Adults with Growth Hormone Deficiency in the Dynamics of Recombinant Growth Hormone Therapy
Aim of the investigation — to study serum levels of apolipoprotein A1 and B and their ratio in 174 young adults (average age — 22.47 ± 0.30 years) with childhood-onset growth hormone deficiency. Materials and methods....